ArticleProceedings of the National Academy of Sciences of the United States of America2005
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Trial
- Review
- Hypoimmune CD19 CAR T cells treat allogeneic mice with features of spontaneous systemic lupus erythematosus.iScience · 2025Article
- Altered B cell immunoglobulin signature exhibits potential diagnostic values in human colorectal cancer.iScience · 2023Article
- Hematogenous Macrophages Contribute to Fibrotic Scar Formation After Optic Nerve Crush.Molecular neurobiology · 2022Article
- IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases.Cancers · 2022Article
- Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.Frontiers in immunology · 2022Article
- Cryo-EM structure of the B cell co-receptor CD19 bound to the tetraspanin CD81.Science (New York, N.Y.) · 2021Article
- Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering.Antibodies (Basel, Switzerland) · 2020Article
- A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking.eLife · 2020Article
- Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.Frontiers in immunology · 2019Review
- CAR T cells, immunologic and cellular therapies in hematologic malignancies.Best practice & research. Clinical haematology · 2018Article
- BANK1 alters B cell responses and influences the interactions between B cells and induced T regulatory cells in mice with collagen-induced arthritis.Arthritis research & therapy · 2018Article
- B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Therapeutic advances in neurological disorders · 2018Review
- Plasma cell survival in the absence of B cell memory.Nature communications · 2017Article
- Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.British journal of pharmacology · 2017Review
- A lifetime aging study of human CD19 transgenic mice.Transgenic research · 2017Article
- Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.Journal of clinical medicine · 2016Review
- Biology and clinical application of CAR T cells for B cell malignancies.International journal of hematology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Immunotherapy with unconjugated CD20 monoclonal antibodies has proven effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD20 immunotherapy depletes mature B cells but does not effectively deplete pre-B or immature B cells, some B cell subpopulations, antibody-producing cells, or their malignant counterparts. Because CD19 is expressed earlier during B cell development, a therapeutic strategy for the treatment of early lymphoblastic leukemias/lymphomas was developed by using CD19-specific monoclonal antibodies in a transgenic mouse expressing human CD19. Pre-B cells and their malignant counterparts were depleted as well as antibody- and autoantibody-producing cells. These results demonstrate clinical utility for the treatment of diverse B cell malignancies, autoimmune disease, and humoral transplant rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.